Navigation Links
Vermillion Reports Fourth Quarter and Full Year 2012 Results
Date:2/20/2013

uest Diagnostics which were resolved in 2012 (at $60 per resolved test). The resolved tests include both reimbursed and unreimbursed tests for which Quest Diagnostics considers the payment status as final.

By comparison, revenue in the fourth quarter of 2011 included $206,000 of product revenue from 4,118 OVA1 tests performed (at the fixed $50 per test), and $549,000 for the variable 33% royalty from 11,708 OVA1 tests reported by Quest Diagnostics as resolved in 2011 (at $47 per resolved test).

Total revenue for the full year 2012 increased 9% to $2.1 million from $1.9 million in 2011. Total revenue in 2012 was comprised of $1.6 million in product sales of OVA1 and $454,000 in license revenue. Product sales of OVA1 in 2012 include $824,000 from 16,460 OVA1 tests performed (at the fixed $50 per test) and $816,000 from the 33% royalty reported by Quest Diagnostics for 2012.

By comparison, revenue in 2011 included $1.5 million from product sales of OVA1 and $454,000 of license revenue. Product sales of OVA1 in 2011 were comprised of $761,000 from 15,225 OVA1 tests performed (at the fixed $50 per test), $549,000 from the 33% royalty reported by Quest Diagnostics for 2011, and $159,000 from the 33% royalties reported by Quest Diagnostics for 2010. The 2010 royalty was reported by Quest Diagnostics and recorded by the company in the first quarter of 2011.

Total operating expenses in the fourth quarter of 2012 decreased to $2.4 million from $3.9 million in the same year-ago quarter. Operating expenses for the full year 2012 decreased to $11.4 million from $19.4 million in 2011, primarily due to lower clinical trial costs for the ongoing development of the company's ovarian cancer franchise and PAD program, as well as lower overall headcount and stock-based compensation charges compared to the prior year. Research and development expenses for the prior year also included $435,000 for the Correlogic asset acquisition.

Fourth quarter 2012
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion to Present at the 2012 Gateway Conference on September 6
7. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
8. Vermillion Reports Third Quarter 2012 Results
9. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Since last month,s FBI shutdown of online ... the leading online black market for illegal drugs - ... offering of drugs and other illegal items.  New numbers ... succeed in lowering the numbers of drugs and illegal ... in August. But some new sites that have emerged ...
(Date:12/19/2014)... China separating membrane market has witnessed robust development ... years, albeit as a later starter. In 2012, the size ... approximated RMB12 billion, with the proportion worldwide soaring to 16.3%. ... membrane market will continue its growth rate by around 20% ... will jump to roughly RMB25 billion. An integrated ...
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS Asserts its Position in Difficult Environment 2
... 21 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... of its,collaboration with the National Institute of ... institute supporting biodefense,research, under which the NIAID ... late-stage antibiotic, as a treatment for,anthrax and ...
... By ... Year- End 2007, ... focused on discovering and,developing novel RNA interference-based therapeutics, announced today that,it ... at,Buffalo, Center for Hearing & Deafness, which is the Company,s primary ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:12/19/2014)... Oshkosh, Wisconsin (PRWEB) December 19, 2014 ... country music performer is again returning to the stage ... joining her husband for concert performances, and the successful ... show was originally announced. , Visit Ticketability.com ... for the newly-announced Detroit shows at fair prices. , ...
(Date:12/19/2014)... in good shape seems to reduce your risk of high ... more than 57,000 Americans, including more than 35,000 with high ... Those in the poorest shape had a more than ... start of the study, compared to a 50 percent chance ... more than 8,000 people diagnosed with high blood pressure during ...
(Date:12/19/2014)... Randy Dotinga HealthDay ... -- Common painkillers, including ibuprofen, might slightly reduce your ... say. Use of ibuprofen (Advil, Motrin) and naproxen ... skin cancer by 15 percent, the researchers concluded after ... usually caused by sun exposure. These ...
(Date:12/17/2014)... While countless companies tempt patients to buy hCG ... of their purchase. Not only is the sale of hCG ... patients who buy hCG online are typically receiving products that ... real hCG present. Illegal internet hCG is typically manufactured outside ... and may contain unknown fillers that can pose very serious ...
(Date:12/17/2014)... 17, 2014 HeartMath® Inc., recognized ... stress, heart rate variability (HRV), heart coherence and ... extensive HRV databases and algorithms to chipset manufacturers ... enable HeartMath’s partners to offer its HRV solutions, ... as well as its normative HRV databases and ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3
... 14 (HealthDay News) -- Military veterans who attempt suicide are ... have an overall heightened risk of death from all causes, ... in BioMed Central Public Health , looked at the ... Veterans Affairs medical center for a suicide attempt between 1993 ...
... THURSDAY, July 14 (HealthDay News) -- Before the advent of ... information -- such as phone numbers and birthdays -- than you ... the brain just doesn,t remember information as well if the person ... people may remember, however, is where they need to ...
... part of the Target Safely initiative, the American Society for ... of a series of such papers, on the safe use ... oncology clinic. The executive summary of this white paper is ... (PRO), ASTRO,s clinical practice journal. The full text of the ...
... 14 July 2011 Bristol-Myers Squibb today announced that ... treatment of adult patients with previously-treated advanced melanoma. ... the treatment of patients with advanced melanoma in a ... England Journal of Medicine in June 2010.(1) Based ...
... Whether patients with type 2 diabetes mellitus benefit from ... levels through treatment ("intensive blood glucose control") remains an ... a benefit but also of potential harm. This is ... Institute for Quality and Efficiency in Health Care (IQWiG). ...
... , WEDNESDAY, July 13 (HealthDay News) -- A new study ... patients thinking that real and fake drugs were doing the ... had a much greater physical effect on their lungs. ... were breathing much better even if they hadn,t taken a ...
Cached Medicine News:Health News: Can You Google Your Memory? 2Health News: Can You Google Your Memory? 3Health News: Can You Google Your Memory? 4Health News:ASTRO publishes white paper on IMRT safety 2Health News:YERVOY (ipilimumab) approved for the treatment of previously treated advanced melanoma in the EU 2Health News:YERVOY (ipilimumab) approved for the treatment of previously treated advanced melanoma in the EU 3Health News:Benefit of blood glucose lowering to near-normal levels remains unclear 2Health News:Benefit of blood glucose lowering to near-normal levels remains unclear 3Health News:Delving Into the Mystery of Placebos 2Health News:Delving Into the Mystery of Placebos 3
... single-detector system offers general purpose ... for gurneys and wheelchairs. This ... versatile open gantry, caudal/cephalic detector ... for SPECT and whole body ...
Stainless steel lancet blade in stainless steel....
Sharp diamond shaped double blade in stainless steel....
... The ANGIO CT MIYABI ... a Siemens SOMATOM CT scanner ... an AXIOM Multistar angiography unit. ... M angio table, which can ...
Medicine Products: